Welcome to our dedicated page for Ainos SEC filings (Ticker: AIMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ainos, Inc. filings document operating results, material agreements, governance matters, and the securities structure of a Nasdaq-listed company with AIMD common stock and AIMDW warrants. Form 8-K reports cover annual and quarterly financial results, AI Nose commercialization updates, distribution rights for AINOS AI Nose products and services, and amendments to product-development and patent-use arrangements.
The company’s proxy materials disclose director elections, shareholder voting matters, compensation information, and governance procedures. Its filings also describe relationships involving Taiwan Carbon Nano Technology Corporation and Ainos KY, including control and voting-power matters relevant to the company’s corporate governance and development agreements.
ASE Technology Holding and subsidiary ASE Test, Inc. report beneficial ownership of 667,085 shares of Ainos, Inc. common stock, representing 8.4% of the class. This stake combines 11,777 shares held directly with shares issuable from a $2,000,000 2023 convertible note, a $9,000,000 2024 convertible note, and a warrant for 100,000 shares, all reflecting a one-for-five reverse stock split completed in June 2025. The notes bear 6% compound interest and are convertible primarily at $22.50 per share. ASE Test Taiwan has also granted Ainos KY broad voting discretion over its Ainos shares and agreed to annual transfer limits, underscoring a long-term, structured investment relationship.
Ainos, Inc. outlines its dual strategy of commercializing its AI-based scent digitization platform, AI Nose, and advancing its low-dose oral interferon program, VELDONA, while warning of ongoing losses and heavy funding needs. AI Nose targets healthcare and industrial applications, including semiconductor manufacturing, through hardware sales and subscription deployments. VELDONA has completed extensive human and animal studies and holds orphan drug designation for oral warts in HIV-seropositive patients, but none of the human or veterinary drug candidates are yet approved. The company reports minimal 2025 revenue, operating losses of about $14 million, cumulative losses above $67 million, cash of roughly $417 thousand, and emphasizes material dependence on new capital to continue operations.
Ainos, Inc. reported full-year 2025 results and highlighted early commercialization of its AI Nose platform. Revenue reached $124,157, up about 499% from 2024, with gross margin turning positive at roughly 82.9% after a prior-year gross loss.
Despite this top-line growth, Ainos posted a net loss of about $14.8 million, similar to 2024, as operating expenses were roughly $14.1 million. Cash and cash equivalents fell to about $417,353 versus $3.9 million a year earlier. After year-end the company raised NTD 90 million (approximately $2.82 million) to support operations and AI Nose deployment.
For 2026, Ainos is rolling out AI Nose in semiconductor environments, including around 200 systems for front-end wafer fabs and about 1,400 systems under a three-year $2.1 million deployment in semiconductor packaging and testing, with a potential roadmap to scale substantially if validations succeed.
Ainos, Inc. filed Amendment No. 14 to its Schedule 13D updating its ownership in Ainos, Inc., a Texas corporation. The filing reports beneficial ownership of 491,263 shares of common stock, representing 6.76% of the outstanding class. Ainos Inc. (Cayman Islands) also holds sole voting power over 3,536,073 shares, including shares subject to voting agreements with several shareholders and ASE Test, Inc., though these 3,044,810 voting-agreement shares are excluded from its reported beneficial ownership. The amendment notes that Taiwan Carbon Nano Technology Corporation sold 46,000 shares subject to the 2026 Voting Agreement and reiterates that the position is held for investment purposes, while leaving open the possibility of future discussions about strategic transactions.
Taiwan Carbon Nano Technology Corporation (TCNT) updated its ownership and voting arrangements in Ainos, Inc. TCNT now beneficially owns 989,925 shares of Ainos common stock, representing 13.62% of the outstanding shares, after recent sales including 46,000 shares sold on January 28, 2026.
The filing explains that TCNT originally received Ainos shares in August 2024 under a license agreement, in exchange for granting an exclusive, irrevocable, and perpetual license to certain gas sensor and medical device patents. Ainos later implemented a one‑for‑five reverse stock split and TCNT has been gradually selling shares.
On January 1, 2026, TCNT entered into a voting agreement with Ainos Inc., a Cayman Islands corporation, covering the Ainos shares held by TCNT. Under this agreement, TCNT agreed to vote all of its Ainos voting stock as determined by Ainos KY in its sole discretion, effectively transferring voting control while retaining economic ownership.
Taiwan Carbon Nano Technology Corp, a more than 10% owner of Ainos, Inc., reported selling 46,000 shares of Ainos common stock on January 28, 2026 at an average price of $2.1697 per share for general operating purposes.
After this transaction, the reporting shareholder directly owned 989,925 Ainos common shares.
ScentAI Inc., a wholly owned subsidiary of Ainos, Inc., filed a Schedule 13D reporting beneficial ownership of 1,160,000 shares of Ainos common stock, representing 16.50% of the outstanding class. These shares have no voting power for so long as they are held by the wholly owned subsidiary.
ScentAI acquired the 1,160,000 Ainos shares on December 30, 2025 in exchange for 116,000,000 shares of ScentAI common stock. The filing states the stake was acquired for investment and general corporate purposes and notes that ScentAI currently has no specific plans for corporate actions involving Ainos, though it may review and change its intentions over time.
Taiwan Carbon Nano Technology Corp, a 10% owner of Ainos, Inc., reported small open-market sales of Ainos common stock. On January 8, 2026, it sold 850 shares at $1.8048 per share, leaving 1,036,356 shares beneficially owned. On January 9, 2026, it sold an additional 431 shares at $1.86 per share, after which it held 1,035,925 shares directly.
According to the footnote, the reporting person sold these shares of common stock for general operating purposes.
Ainos, Inc. reported that on December 30, 2025 it entered into a distribution agreement with Trusval Technology Co. Ltd. covering its AINOS AI Nose and related products and services. The agreement runs for three years and provides Trusval with one-year exclusive distribution rights for Products sold to certain clients, after which exclusivity may change according to the contract terms. This arrangement is intended to govern how Ainos’ AI Nose offerings reach designated customers through Trusval as a distributor.
Ainos, Inc. (AIMD) reported that one of its directors acquired additional equity in the company. On November 25, 2025, the director received 50,000 shares of common stock as special stock awards at a price of $2.10 per share, increasing the director’s holdings to 91,280 shares held directly. The filing shows related derivative entries for 50,000 RSUs that were acquired and then converted into the same number of common shares on the same date.
The company’s stockholders had previously approved these special stock awards on November 7, 2025, indicating that this equity grant was part of an authorized compensation arrangement. This transaction aligns the director’s interests more closely with the performance of Ainos, Inc. through a larger direct ownership stake.